Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.42 |
| ▸ | MET | P08581 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2688404 | 0.93 | MET (0.43) | CYP11B2METCYP11B1ALDH1A1KDM4E | |
| SCHEMBL2686059 | 0.90 | OPRM1 (0.43) | CYP11B2METCYP11B1ALDH1A1KDM4E | |
| SCHEMBL2686700 | 0.89 | CYP11B2 (0.57) | CYP11B2METCYP11B1ALDH1A1KDM4E | |
| SCHEMBL2688761 | 0.87 | NPC1 (0.46) | CYP11B2METCYP11B1ALDH1A1KDM4E | |
| SCHEMBL2686061 | 0.86 | NPC1 (0.47) | METALDH1A1KDM4ENPC1HPGD | |
| SCHEMBL2686461 | 0.86 | MET (0.41) | CYP11B2METCYP11B1ALDH1A1KDM4E | |
| SCHEMBL2688684 | 0.85 | MET (0.44) | METALDH1A1KDM4ENPC1HPGD | |
| SCHEMBL2687682 | 0.85 | CNR1 (0.44) | CYP11B2METCYP11B1ALDH1A1KDM4E | |
| SCHEMBL2687569 | 0.85 | MET (0.40) | METALDH1A1KDM4ENPC1HPGD | |
| SCHEMBL10219917 | 0.85 | MET (0.43) | METALDH1A1KDM4ENPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829035-B2 | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829035-B2 | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829035-B2 | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| EP-2436683-B1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL CO (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-10 | — | — | US | disclosed |
| WO-2010137349-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | 住友化学株式会社 (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | BDNF, NGF, NTRK2 | CYP11B2 1055/4885MET 41/4885CYP11B1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.